{"name":"NKarta","slug":"nkarta","ticker":"NKTX","exchange":"NASDAQ","domain":"nkartatx.com","description":"NKarta is a biotechnology company focused on developing cell therapies for the treatment of various diseases. The company's lead product candidate, NKX101, is an allogeneic natural killer (NK) cell therapy being developed for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). NKarta's technology platform enables the scalable and cost-effective production of NK cells for use in cancer immunotherapy.","hq":"South San Francisco, CA","founded":0,"employees":"","ceo":"Paul B. Bolber","sector":"Cell Therapy / Immuno-Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$450M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":90429000,"netIncome":-104084000,"cash":39634000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"NKarta Announces FDA Clearance of IND for NKX101","summary":"NKarta announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for NKX101, the company's lead product candidate.","drugName":"NKX101","sentiment":"positive"},{"date":"2023-11-14","type":"deal","headline":"NKarta Announces Collaboration with Pfizer to Develop NK Cell Therapies","summary":"NKarta announced a collaboration with Pfizer to develop and commercialize NK cell therapies for the treatment of various cancers.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1rSkhhR1MySTdrVUFHSjJmYlVxSk5nOVdaYVo3Z0ZiVndBRFFyaEFfN0ZGTDlSNTNnUnNvdWpWZklmTzlBdEhVWnhZdmRZdTVNa25tV09vZlNVUFFWWXBKeWZiX190MmFhTTdGR0tn?oc=5","date":"2026-04-08","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Nkarta, Inc. (NKTX) - Stock Titan","headline":"If You Invested $1,000 in Nkarta, Inc. (NKTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxOMy1RWFhOSnE5MFgtSXliWXNFZXpLdWRWYUZsZlZmVldhS19SckR0aGxHZ2ZROUxLVHhJOTd5VWdPb3lUdFhBbFQxbmJHcng2bnZmcFBZVEd1MGdNZVBRczd2T2w1TVhtQnpCRlRMSmZzNks3a3ktOHVNZ0k4QVVhdVV4ZWU1RXpablNweGd3bGN4MjR1dlZGejdPQWRxdjJQMnVzTVNQczZKLUQzNDktNUFqYy1nZC1EU1pSMVdXRFZCTFBmYXdQU2NTbHFsNzRhYTZfelNnajNOaVVPSlUyamdKZFFKRlUwTXdDdlo0WnFPYWROd1lMUGhlZ0NEUC1xbnNabDhhVzMtdzl2R1ZzWVZ2eXphX3Znb3k3Y2FFdw?oc=5","date":"2026-03-27","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), QT Imaging Holdings (QTI) and Cardiff Oncology (CRDF) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), QT Imaging Holdings (QTI) and Cardiff Oncology (CRDF)","sentiment":"neutral"},{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPc3JpeDBKMUd0S3ZGY0xaREZXU3o4TkxaTFJ0RXV2clhya3RHZzV5SEFRMXhiTTlsOWlCY3FDWUJGYUNPOUNvOUZzN1l4LUNrM2pHRHE0b0pBTXJXRVNFbFpOci1PTHRzSDBYa1pqa29MSVRzZWFoXzFzbXV6aE5CeEJ1enJ5WlhtUkxHYmtaSVY?oc=5","date":"2026-03-24","type":"earnings","source":"Defense World","summary":"Nkarta (NKTX) to Release Earnings on Tuesday - Defense World","headline":"Nkarta (NKTX) to Release Earnings on Tuesday","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNRC14aWZ1ZkJVU3ZWZi0tVjF6MGJsVlJSQzgzWTRYNXlUT1BzaHNCenVFRklMV3RnYjg3MmRnck9YTHlJOG5LXzlmVmw2UGNYMlV1S0xiWGlnLXAtVlFPUnBmVExJNzNwb3JOZVQzc0ZFN0ZPNEMtV3JjaVVyWnJia3I2WlVRc1RYOHB2OENoTFlmQmUzTVBwLVJ3RHZNSmJoNWJCTmVhMG5IZ1pfV1czZGs3aXI2MU05TTUxWEVJYnZNbEU?oc=5","date":"2026-02-17","type":"pipeline","source":"Stock Titan","summary":"Tang Capital discloses 2.1% Nkarta (NKTX) ownership in Schedule 13G/A - Stock Titan","headline":"Tang Capital discloses 2.1% Nkarta (NKTX) ownership in Schedule 13G/A","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-23","type":"pipeline","source":"simplywall.st","summary":"Nkarta Insiders Make Handsome Sum Selling Stock At US$2.06 Per Share - simplywall.st","headline":"Nkarta Insiders Make Handsome Sum Selling Stock At US$2.06 Per Share","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPbjg0cWFxQ0l2YmpHMUd0OUJPRzd2ZTdsX2ZGREgzdzBNVkdlRW5faF9LLVhGeWVRa3htNnM0UndHTFdZQzd0ajRud2VubF9rWEI1Y0ZGclVZcjhxcllaMDQ2aFJIbG9pSGNHcDhDWTdrc0tocmhndENsUGprTWRnOWxYNV95Z1JpaXczVGdCZDQ3NlRxY0tYWTB3N2VlX1po?oc=5","date":"2025-12-02","type":"pipeline","source":"Stock Titan","summary":"Nkarta (Nasdaq: NKTX) to speak at Evercore 8th Annual Healthcare Conference - Stock Titan","headline":"Nkarta (Nasdaq: NKTX) to speak at Evercore 8th Annual Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNMVVuaTROd2UzLUhiQm55WTdZaXdTTEZZcjVKTktROWNrQmNUNlk5dk1aS0RLWmRDLTZGSmdJUHdpUXcyMm5HbmNYVkRsTVY4WGVFZzkxUkJFV3dIZkpyTUVyeWpKUjhGRUNpYTNQSDFuTjdIMl9ORnZxblY1S25qNEdRMHk3UFZEeGFSRFFSN3UyNnZ4V1diU1Y1ejFuY2Rrcmw5cV9IMEt5ZmFnRFBhbk5xZHhyXzlpdXhCMHc4TWF0LWRrWWoxR1Nn?oc=5","date":"2025-11-22","type":"pipeline","source":"Seeking Alpha","summary":"Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason - Seeking Alpha","headline":"Nkarta: Pushing Deeper And Deeper Into A Discount Vs. Their Holdings, For No Real Reason","sentiment":"neutral"},{"date":"2025-11-10","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-01","type":"pipeline","source":"simplywall.st","summary":"Is Nkarta (NASDAQ:NKTX) In A Good Position To Deliver On Growth Plans? - simplywall.st","headline":"Is Nkarta (NASDAQ:NKTX) In A Good Position To Deliver On Growth Plans?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5DM05TQ2Y1Y2dPaHo0ZnZYVGZaaWF0VVBKRmtsQld3akpPOUpRVXdIYW5aTHoybWt0ZkUzY1dsMENpLW9PY3BDV2h5VmJaR3VLRjNzYUhIQ1JWa2JVVW9oYk9ObnIxd0hz?oc=5","date":"2025-10-22","type":"regulatory","source":"MarketBeat","summary":"Nkarta (NKTX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat","headline":"Nkarta (NKTX) FDA Approvals, PDUFA Dates & Drug Alerts 2026","sentiment":"positive"},{"date":"2025-08-12","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Gilead Sciences","Novartis"],"therapeuticFocus":["Oncology","Immunology"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":0,"period":"2025-12-31"},{"value":0,"period":"2024-12-31"},{"value":0,"period":"2021-12-31"},{"value":0,"period":"2020-12-31"},{"value":115000,"period":"2019-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":90429000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-104084000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":39634000,"cashHistory":[],"totalAssets":404209000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}